HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Submassive hepatic necrosis distinguishes HBV-associated acute on chronic liver failure from cirrhotic patients with acute decompensation.

AbstractBACKGROUND & AIMS:
Distinguishing between acute on chronic liver failure (ACLF) and decompensated liver cirrhosis is difficult due to a lack of pathological evidence.
METHODS:
A prospective single-center study investigated 174 patients undergoing liver transplantation due to acute decompensation of hepatitis B virus (HBV)-associated liver cirrhosis. Two groups were distinguished by the presence or absence of submassive hepatic necrosis (SMHN, defined as necrosis of 15-90% of the entire liver on explant). Core clinical features of ACLF were compared between these groups. Disease severity scoring systems were applied to describe liver function and organ failure. Serum cytokine profile assays, gene expression microarrays and immunohistochemical analyzes were used to study systemic and local inflammatory responses.
RESULTS:
SMHN was identified in 69 of 174 patients proven to have cirrhosis by histological means. Characteristic features of SMHN were extensive necrosis along terminal hepatic veins and spanning multiple adjacent cirrhotic nodules accompanied by various degrees of liver progenitor cell-derived regeneration, cholestasis, and ductular bilirubinostasis. Patients with SMHN presented with more severely impaired hepatic function, a higher prevalence of multiple organ failure (as indicated by higher CLIF-SOFA and SOFA scores) and a shorter interval between acute decompensation and liver transplantation than those without SMHN (p<0.01 for all parameters). Further analyzes based on serum cytokine profile assays, gene expression microarrays and immunohistochemical analyzes revealed higher levels of anti-inflammatory cytokines in patients with SMHN.
CONCLUSIONS:
SMHN is a critical histological feature of HBV-associated ACLF. Identification of a characteristic pathological feature strongly supports that ACLF is a separate entity in end-stage liver disease.
AuthorsHai Li, Qiang Xia, Bo Zeng, Shu-Ting Li, Heng Liu, Qi Li, Jun Li, Shu-Yin Yang, Xiao-Jun Dong, Ting Gao, Stefan Munker, Yan Liu, Roman Liebe, Feng Xue, Qi-Gen Li, Xiao-Song Chen, Qiang Liu, Hui Zeng, Ji-Yao Wang, Qing Xie, Qin-Hua Meng, Jie-Fei Wang, Peter R Mertens, Frank Lammert, Manfred V Singer, Steven Dooley, Matthias P A Ebert, De-Kai Qiu, Tai-Ling Wang, Hong-Lei Weng
JournalJournal of hepatology (J Hepatol) Vol. 63 Issue 1 Pg. 50-9 (Jul 2015) ISSN: 1600-0641 [Electronic] Netherlands
PMID25646889 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Hepatitis B Antibodies
Topics
  • Acute-On-Chronic Liver Failure (diagnosis, surgery)
  • Diagnosis, Differential
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Hepatitis B Antibodies (immunology)
  • Hepatitis B virus (immunology)
  • Humans
  • Liver (pathology)
  • Liver Cirrhosis (diagnosis)
  • Liver Transplantation
  • Male
  • Middle Aged
  • Necrosis (diagnosis)
  • Prognosis
  • Prospective Studies
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: